Predictors of treatment outcomes following anti-vascular endothelial growth factor (VEGF) therapy for Neovascular AMD.

新生血管性 AMD 抗血管内皮生长因子 (VEGF) 治疗后治疗结果的预测因素。

• 批准号: nhmrc : 590205
• 负责人: Prof Paul Baird
• 金额: $ 16.02万
• 依托单位: Centre for Eye Research Australia Ltd
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2010
• 资助国家: 澳大利亚
• 起止时间: 2010-01-01 至 2012-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/predictors-treatment-outcomes-neovascular-amd/100369
• 关键词: Predictors; treatment; outcomes; following; anti

Age-related macular degeneration (AMD) is the most common cause of severe, irreversible loss of vision amongst elderly populations in the developed world. Bleeding in the retina destroys central vision. New treatments have been developed to stop this bleeding. However not all patients benefit equally, with some still losing vision. This project aims to investigate what determines how well an individual responds to treatment, in particular, how genes might influence the response.

年龄相关性黄斑变性 (AMD) 是发达国家老年人口严重、不可逆视力丧失的最常见原因。视网膜出血会破坏中央视力。已经开发出新的治疗方法来止血。然而，并非所有患者都能平等受益，有些患者仍然失去视力。该项目旨在调查决定个体对治疗反应程度的因素，特别是基因如何影响反应。